ClinicalTrials.gg
RecruitingNCT06802588OPT-ICHUpdated Jan 15, 2026

Optimization of the Management of Non-Traumatic Intracerebral Hemorrhage (OPT-ICH)

An observational study in Intracerebral Hemorrhage, sponsored by University Hospital, Tours. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by University Hospital, Tours · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Cerebral Hemorrhage with a site in France — 11 open to participants now, 11 under way, 2 of them phase 3. Cerebral Hemorrhage · France.

Planned enrollment
4th of 11
600 · median 455
Started
2022
the only one that year
Observational
11 of 24
7 open now
Primary completion
2027-05
later than 3 of 10 live
Registered
17th of 24
by date
Lead sponsor
2 of 24
University Hospital, Tours

Among the 24 studies in Cerebral Hemorrhage with a site in France, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2022, is one of 11 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 17th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

11 of the 24 studies in Cerebral Hemorrhage with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Cerebral Hemorrhage with a site in France, or all of them as a file.
02

Study summary

Intracerebral non-traumatic intraparenchymal hemorrhages (ICH) account for 15 to 20% of strokes. One third of the patients dies within the month following ICH, and survivors often experience residual disability with a high risk of recurrent ICH, other serious vascular events, and neurological complications such as epilepsy and dementia. Encouraging but preliminary data suggest a favorable trend in terms of survival rates in recent years. This is partly due to improved management of patients with ICH, which must be early (the concept of "time is brain") and carried out by expert personnel (medical and paramedical) in specialized units.

The main objectives of the study are:

  • To evaluate the management of patients with ICH in the acute phase within the University Hospital of Tours by analyzing the procedures adopted in the various relevant departments (neurovascular units, neurosurgery, medical or neurosurgical intensive care, geriatrics);
  • To evaluate whether the systematic implementation of a dedicated protocol (see *) for the management of patients with ICH is associated with a reduction in mortality and disability in the short and long term.
Read the detailed description

The project consists of 2 parts:

  • Retrospective, multicentric, observational study. Inclusion of all patients presenting with ICH admitted urgently to the University Hospital of Tours between 2018-2021.
  • Prospective, multicentric, observational study. Inclusion of all patients presenting with ICH admitted urgently to the University Hospital of Tours, Angers and Poitiers.

Each patient will benefit from management according to a protocol which will include:

  • Emergency MRI with contrast injection (contrast-enhanced brain CT scan if contraindicated);
  • Admission to the Neurovascular Unit unless hemodynamically unstable or intubated;
  • First intravenous antihypertensive injection with a goal \< 1 hour from arrival at the hospital;
  • Anticoagulation reversal with a goal \< 1 hour from arrival at the hospital;
  • Standard laboratory tests + coagulation study ;
  • Neurosurgical consultation upon arrival at the department;
  • Follow-up MRI at 24-48 hours or earlier if clinical worsening;
  • Diagnostic work-up for the evaluation of hypertension-related end organ damage (Transthoracic echocardiogram, retinography , proteinuria);
  • Contrast-enhanced follow-up MRI at 3-6 months;
  • Neurological evaluation at 6 months and 2 years;
  • When applicable a neuropsychological evaluation at 6M and 2 Y;
03

Conditions studied

  • Intracerebral Hemorrhage

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult population with acute ICH

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged over 18 years
  • emergency admission to the University Hospital of Tours
  • having an ICH on imaging performed upon admission (CT scan or MRI) at the University Hospital of Tours

Exclusion criteria

Exclusion criteria :

- Patient who has given their opposition to the collection of their data

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. mortality and disability

    Primary Outcome Measure Title: Modified Rankin Scale (mRS) Scores to Assess Disability and Mortality Description: The study will evaluate functional outcomes, disability, and mortality in patients with non-traumatic intracerebral hemorrhage. Functional outcomes will be measured using the modified Rankin Scale (mRS), which evaluates the degree of disability or dependence in daily activities. The mRS scores range from 0 (no symptoms) to 6 (death). Data will be summarized as the proportion of participants in each mRS category at 6 months and 2 years. Mortality will be assessed as the percentage of participants with an mRS score of 6.

    Time frame: 6 months, 2 years

Secondary outcomes

  1. Neuropsychiatric patient profile among the survivors

    Cognitive and behavioral outcomes will be measured using a battery of neuropsychiatric tests, including assessments for memory, executive function, attention, and mood disorders (e.g., depression and anxiety). Data will be reported as mean test scores for each domain

    Time frame: 6 months, 2 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for May 2027, 60 months after the start.

Of 88 non-industry observational studies under Cerebral Hemorrhage, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 179. This study's planned 60 months is close to that.

Counting every sponsor, half of 90 studies reached it within 62 months; a quarter within 27 and three quarters within 179.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 31, 2025
StartActual
May 1, 2022
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06802588
Responsible party
Sponsor
First posted
Jan 31, 2025
Start date
May 1, 2022
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jan 15, 2026

Study contacts

Marco PASI, MD, PHD
Contact
M.PASI@chu-tours.fr
+33 0247478024
Marco PASI, MD, PHD
principal investigator · neurovascular unit, neurology department, CHRU Tours
Grégoire Boulouis, MD, PHD
principal investigator · interventionnal neuroradiology unit, neuroradiology department, CHRU Tours

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion